Partnering with Akretiv provides life sciences companies with a financially de-risked pathway into the animal health market. Animal-specific clinical development and regulatory work are funded by external investors through Akretiv-managed SPVs, allowing you to expand into a new market without deploying internal capital. You retain full control over core IP, human development, and manufacturing, while the SPV manages animal health–specific branding, target-species clinical data (shared), regulatory approvals, and commercialization rights.

Akretiv offers flexible deal structures ranging from traditional out-licensing to fully integrated co-development partnerships, designed to maximize value for both human life sciences partners and animal health investors.

This model can generate early financial returns through upfront payments, program milestones, royalties, and supply agreements, while also providing valuable translational insights from animal studies and early manufacturing feedback, potentially accelerating timelines for human therapeutics.

For Akretiv, the model unlocks value from innovative, partially de-risked assets to build a pipeline that would otherwise not be consider for animal health deployment. The primary value inflection occurs at program completion, with asset-level exits through licensing or distribution agreements with strategic animal health companies.

Why work with Akretiv?

• Akretiv provides a dedicated team with deep animal health expertise

• Akretiv has relationships with animal health pharmaceutical companies (potential distribution deals, strategic exits)

• Efficient development for funding (including convertible loans model)